EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prevalence Estimates of Cytochrome P450 Phenoconversion in Youth Receiving Pharmacotherapy for Mental Health Conditions

Samuel Gerlach, Abdullah Al Maruf iD, Sarker M Shaheen, Ryden McCloud, Madison Heintz iD, Laina McAusland iD, Paul D Arnold iD, Chad A Bousman iD

Clinical Pharmacology & Therapeutics · 2025-03 · 117 (3) · 670-675

DOI: 10.1002/cpt.3534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 17.12.2024. Verfasst von Samuel Gerlach und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Mental Disorders, Cytochrome P-450 Enzyme System. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alberta Children's Hospital Foundation Child Health Grant, University of Calgary O'Brien Centre Summer Studentship, Alberta Innovates Translational.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenetics‐predicted drug metabolism may not match clinically observed metabolism due to a phenomenon known as phenoconversion. Phenoconversion can occur when an inhibitor or inducer of a drug‐metabolizing enzyme is present. Although estimates of phenoconversion in adult populations are available, prevalence estimates in youth populations are limited. To address this gap, we estimated the prevalence of phenoconversion in 1281 youth (6–24 years) receiving pharmacotherapy for mental health conditions and who had pharmacogenetics testing completed for four genes ( CYP2B6 , CYP2C19 , CYP2D6 , CYP3A4 ). Self‐reported medication and cannabidiol/cannabis use were collected at the time of pharmacogenetics testing. Nearly, half (46%) of the cohort was estimated to be phenoconverted for one of the four genes examined. Comparison of metabolizer phenotype frequencies before and after adjustment for phenoconversion showed significantly more youth had actionable phenotypes for CYP2C19 (60.3% vs. 69.1%; P =< 0.001), CYP2D6 (49.3% vs. 63.0%; P =< 0.001), and CYP3A4 (8.5% vs.12.2%; P = 0.003) after phenoconversion adjustment. Of youth who were phenoconverted, 24% had a change in their metabolizer phenotype that would lead to current pharmacogenetics‐based prescribing guidelines recommending a change to standard prescribing (dose adjustment, alternative medication). Our findings indicate a high prevalence of cytochrome P450 phenoconversion among youth receiving pharmacotherapy for mental health conditions. Adjustment for phenoconversion should be considered when implementing pharmacogenetics testing in youth populations to improve the clinical utility of this testing in practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mental DisordersCytochrome P-450 Enzyme SystemHumansAdolescentMaleFemaleYoung AdultChildCytochrome P-450 CYP2D6Cytochrome P-450 CYP2C19PhenotypePrevalenceCytochrome P-450 CYP3ACannabidiolPharmacogeneticsCytochrome P-450 CYP2B6Pharmacogenomic Testing

Substanzen

Cytochrome P-450 CYP2D6Cytochrome P-450 CYP2C19Cytochrome P-450 Enzyme SystemCYP2C19 protein, humanCytochrome P-450 CYP3ACYP3A4 protein, humanCannabidiolCytochrome P-450 CYP2B6

Autor:innen und Institutionen

  • Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.
  • The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
  • Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Abdullah Al Maruf, Madison Heintz, Laina McAusland, Paul D Arnold, Chad A Bousman

Förderung

  • Alberta Children's Hospital Foundation Child Health Grant
  • University of Calgary O'Brien Centre Summer Studentship
  • Alberta Innovates Translational

Zitieren

APA

Gerlach, S., Maruf, A. A., Shaheen, S. M., McCloud, R., Heintz, M., McAusland, L., Arnold, P. D., & Bousman, C. A. (2025). Prevalence Estimates of Cytochrome P450 Phenoconversion in Youth Receiving Pharmacotherapy for Mental Health Conditions. Clinical Pharmacology & Therapeutics, 117(3), 670-675. https://doi.org/10.1002/cpt.3534

Vancouver

Gerlach S, Maruf AA, Shaheen SM, McCloud R, Heintz M, McAusland L, et al. Prevalence Estimates of Cytochrome P450 Phenoconversion in Youth Receiving Pharmacotherapy for Mental Health Conditions. Clinical Pharmacology & Therapeutics. 2025;117(3):670-675. doi:10.1002/cpt.3534

BibTeX
@article{Gerlach2025,
  author = {Gerlach, Samuel and Maruf, Abdullah Al and Shaheen, Sarker M and McCloud, Ryden and Heintz, Madison and McAusland, Laina and Arnold, Paul D and Bousman, Chad A},
  title = {Prevalence Estimates of Cytochrome P450 Phenoconversion in Youth Receiving Pharmacotherapy for Mental Health Conditions},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {3},
  pages = {670--675},
  doi = {10.1002/cpt.3534}
}
Kostenlos starten →